Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Return on Capital Employed data on record, last reported at 0.02% in Q3 2025.

  • For Q3 2025, Return on Capital Employed rose 47.0% year-over-year to 0.02%; the TTM value through Sep 2025 reached 0.02%, up 47.0%, while the annual FY2024 figure was 0.38%, N/A changed from the prior year.
  • Return on Capital Employed reached 0.02% in Q3 2025 per GLUE's latest filing, down from 0.04% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.04% in Q2 2025 and bottomed at 0.62% in Q4 2023.
  • Average Return on Capital Employed over 3 years is 0.31%, with a median of 0.41% recorded in 2024.
  • Peak YoY movement for Return on Capital Employed: rose 25bps in 2024, then soared 58bps in 2025.
  • A 3-year view of Return on Capital Employed shows it stood at 0.62% in 2023, then skyrocketed by 40bps to 0.37% in 2024, then surged by 107bps to 0.02% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Capital Employed were 0.02% in Q3 2025, 0.04% in Q2 2025, and 0.01% in Q1 2025.